Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2013 21:15 ET | Source: Alcobra Ltd.

Alcobra Ltd. Prices Public Offering of $33 Million of Ordinary Shares

TEL AVIV, ISRAEL, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) , an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
October 21, 2013 05:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Present at AACAP's 60th Annual Meeting on October 24th

TEL AVIV, Israel, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that it will be presenting at AACAP's 60th Annual Meeting. The conference is being held at the Walt...
October 14, 2013 07:35 ET | Source: Alcobra Ltd.

Alcobra Ltd. Announces New Findings on Novel Mechanism of Action for its Proprietary Drug, MG01CI, for Treatment of Cognitive Dysfunctions

Data from preclinical studies link MG01CI to established molecular targets and neurophysiological activities involved in learning and memory MG01CI shows no effect on dopamine or noradrenaline...
October 02, 2013 09:31 ET | Source: Alcobra Ltd.

Alcobra Ltd. Selects CNS Clinical Trials Expert Premier Research as CRO for Phase III Clinical Study of MG01CI as a Treatment for Adults With ADHD

TEL AVIV, Israel, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its...
September 25, 2013 05:00 ET | Source: Alcobra Ltd.

Alcobra to Present Fragile X Study Results at 2013 FRAXA Investigators Meeting

TEL AVIV, ISRAEL, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
September 19, 2013 06:39 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Present at the Aegis Capital 2013 Annual Healthcare Conference on September 26th in Las Vegas

TEL AVIV, Israel, Sept. 19, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that the Company will be presenting at the Aegis Capital 2013 Annual Healthcare Conference. The...
September 10, 2013 05:00 ET | Source: Alcobra Ltd.

Alcobra's Pre-Clinical Fragile X Study for MG01CI Shows Significant Positive Results

TEL AVIV, Israel, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
September 03, 2013 07:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Present at the Stifel Nicolaus 2013 Annual Healthcare Conference on September 11th

TEL AVIV, Israel, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that the Company will be presenting at the Stifel Nicolaus 2013 Annual Healthcare Conference. The...
August 26, 2013 05:00 ET | Source: Alcobra Ltd.

Alcobra Enrolls First Patient in Comparative Study of Executive Function Benefits in Patients With PI-ADHD

TEL AVIV, Israel, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
August 06, 2013 07:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. Reports Second Quarter 2013 Results

TEL AVIV, Israel, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its...